Capricor Therapeutics Inc (CAPR) is a publicly traded Healthcare sector company. As of May 21, 2026, CAPR trades at $30.24 with a market cap of $1.62B and a P/E ratio of -24.46. CAPR moved +7.82% today. Year to date, CAPR is +16.93%; over the trailing twelve months it is +163.49%. Its 52-week range spans $4.30 to $40.37. Analyst consensus is strong buy with an average price target of $54.50. Rallies surfaces CAPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CAPR SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $30.24 |
| Market Cap | $1.62B |
| P/E Ratio | -24.46 |
| EPS | $-1.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.37 |
| 52-Week Low | $4.30 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $22.27M |
| Net Income | $-40.47M |
| Gross Margin | 0.00% |
8 analysts cover CAPR: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.50.